Dose painting for re-irradiation of head and neck cancer

被引:11
|
作者
Skjotskift, Torleiv [1 ]
Evensen, Morten E. [1 ]
Furre, Torbjorn [2 ]
Moan, Jon M. [1 ]
Amdal, Cecilie D. [1 ]
Bogsrud, Trond V. [3 ,4 ,5 ]
Malinen, Eirik [2 ,6 ]
Dale, Einar [1 ]
机构
[1] Oslo Univ Hosp, Dept Oncol, N-0424 Oslo, Norway
[2] Oslo Univ Hosp, Dept Med Phys, Oslo, Norway
[3] Oslo Univ Hosp, Dept Nucl Med, Oslo, Norway
[4] Aarhus Univ Hosp, Dept Nucl Med, Aarhus, Denmark
[5] Aarhus Univ Hosp, PET Ctr, Aarhus, Denmark
[6] Univ Oslo, Dept Phys, Oslo, Norway
关键词
INTENSITY-MODULATED RADIOTHERAPY; SQUAMOUS-CELL CARCINOMA; PHASE-I TRIAL; PROGNOSTIC-FACTORS; RADIATION-THERAPY; RECURRENT HEAD; NUMBERS; DELINEATION; ESCALATION; ORGANS;
D O I
10.1080/0284186X.2018.1512753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: For patients with recurrent or second primary disease, re-irradiation can be challenging due to overlap with previously irradiated volumes. Dose painting may be attractive for these patients, as the focus is on delivering maximal dose to areas of high tumor activity. Here, we compare dose painting by contours (DPBC) treatment plans based on F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) with conventional plans. Material and methods: We included 10 patients with recurrent or second primary head and neck cancer (HNC) eligible for re-irradiation. Our conventional re-irradiation regimen is hyperfractionated radiotherapy 1.5 Gy twice daily over 4 weeks, giving a total dose of 60 Gy. For DPBC, we defined two prescription volumes, PV33 and PV66, corresponding to 33 and 66% of the highest FDG uptake in the tumor. The clinical target volume (CTV) prescription dose was 60 Gy, PV33; 65-67 Gy and PV66; 70-73 Gy. The DPBC plan is to be given the first 20 fractions and the conventional plan the last 20 fractions. Dose to organs at risk (OARs) were compared for DPBC and conventional treatment. By summation of the initial curative plan and the re-irradiation plan, we also evaluated differences in dose to the 2 ccm hot spot (D-2cc). Results: We achieved DPBC plans with adequate target coverage for all 10 patients. There were no significant differences in OAR doses between the standard plans and the DPBC plans (p=.7). Summation of the initial curative plan and the re-irradiation plan showed that the median D-2cc increased from 130 Gy (range 113-132 Gy; conventional) to 140 Gy (range 115-145 Gy; DPBC). Conclusions: Our proposed DPBC could be straightforwardly implemented and all plans met the objectives. Re-irradiation of HNC with DPBC may increase tumor control without more side effects compared to conventional radiotherapy.
引用
收藏
页码:1693 / 1699
页数:7
相关论文
共 50 条
  • [1] Re-irradiation of Head and Neck Cancer-Impact of Total Dose on Outcome
    Janssen, S.
    Baumgartner, M.
    Bremer, M.
    Warszawski, A.
    Stieve, M.
    Eckardt, A.
    Karstens, J. -H.
    Meyer, A.
    ANTICANCER RESEARCH, 2010, 30 (09) : 3781 - 3786
  • [2] Overlapping volumes in re-irradiation for head and neck cancer - an important factor for patient selection
    Embring, Anna
    Onjukka, Eva
    Mercke, Claes
    Lax, Ingmar
    Berglund, Anders
    Bornedal, Sara
    Wennberg, Berit
    Friesland, Signe
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [3] Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review
    Dionisi, F.
    Fiorica, F.
    D'Angelo, E.
    Maddalo, M.
    Giacomelli, I
    Tornari, E.
    Rosca, A.
    Vigo, F.
    Romanello, D.
    Cianchetti, M.
    Tommasino, F.
    Massaccesi, M.
    Orlandi, E.
    ORAL ONCOLOGY, 2019, 98 : 35 - 47
  • [4] The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer
    Ruehle, Alexander
    Sprave, Tanja
    Kalckreuth, Tobias
    Stoian, Raluca
    Haehl, Erik
    Zamboglou, Constantinos
    Laszig, Roland
    Knopf, Andreas
    Grosu, Anca-Ligia
    Nicolay, Nils H.
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [5] Outcome after Re-Irradiation of Head and Neck Cancer Patients
    Platteaux, Nele
    Dirix, Piet
    Vanstraelen, Bianca
    Nuyts, Sandra
    STRAHLENTHERAPIE UND ONKOLOGIE, 2011, 187 (01) : 23 - 31
  • [6] Re-irradiation for recurrent or second primary head and neck cancer
    Lee, Hye In
    Kim, Jin Ho
    Ahn, Soon-Hyun
    Chung, Eun-Jae
    Keam, Bhumsuk
    Eom, Keun-Yong
    Jeong, Woo-Jin
    Kim, Ji-Won
    Wee, Chan Woo
    Wu, Hong-Gyun
    RADIATION ONCOLOGY JOURNAL, 2021, 39 (04): : 279 - 287
  • [7] Re-Irradiation for Head and Neck Cancer: Cumulative Dose to Organs at Risk and Late Side Effects
    Embring, Anna
    Onjukka, Eva
    Mercke, Claes
    Lax, Ingmar
    Berglund, Anders
    Bornedal, Sara
    Wennberg, Berit
    Dalqvist, Emmy
    Friesland, Signe
    CANCERS, 2021, 13 (13)
  • [8] Re-irradiation of head and neck carcinoma
    Mendenhall, William M.
    Mendenhall, Charles M.
    Malillapa, Robert S.
    Palta, Jatinder R.
    Mendenhall, Nancy P.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (04): : 393 - 398
  • [9] Re-irradiation for head and neck cancer: outcome and toxicity analysis using a prospective single institution database
    Scolari, Chiara
    Buchali, Andre
    Franzen, Achim
    Foerster, Robert
    Windisch, Paul
    Bodis, Stephan
    Zwahlen, Daniel R.
    Schroeder, Christina
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [10] Regional cumulative maximum dose to the spinal cord in head-and-neck cancer: Considerations for re-irradiation
    Stoiber, Eva M.
    Schwarz, Michael
    Debus, Juergen
    Huber, Peter E.
    Bendl, Rolf
    Giske, Kristina
    RADIOTHERAPY AND ONCOLOGY, 2013, 106 (01) : 96 - 100